|
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. |
|
|
Honoraria - Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Janssen; Janssen (Inst); MSD Oncology; MSD Oncology (Inst); Roche; Seagen |
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); CureVac (Inst); Exelixis (Inst); Incyte (Inst); Janssen Oncology (Inst); Medivation (Inst); MSD Oncology (Inst); Nektar (Inst); Oncogenex (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol Myers Squibb Foundation; Eisai; EMD Serono; Exelixis; Incyte; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Seagen |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Incyte; Ipsen; Johnson & Johnson; MSD; Novartis; Pfizer; Roche; Seagen |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Ipsen (Inst); Johnson & Johnson (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche |
|
Miguel Ángel Climent Durán |
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Bayer; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Janssen-Cilag; Merck; Pfizer; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Janssen; Merck; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Rainier Therapeutics |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre |
Research Funding - Millennium (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Ipsen; MSD Oncology; Pfizer |
|
|
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME |
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma |
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst) |
Expert Testimony - Celgene; sanofi |
|
|
|
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; GlaxoSmithKline; HERON; Janssen; Merck; Mirati Therapeutics; Pfizer; QED Therapeutics; Roche; Seagen |
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Kure It Cancer Research (Inst); Merck (Inst); Pfizer (Inst); QED Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genzyme; Immunomedics; Incyte; Medscape; Merck; MSD; Pfizer; Roche; UroToday |